Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mineralys TherapeuticsMLYS -0.61%35 Market Cap is $2,308.87 Mil as of Jul. 30, 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Mineralys Therapeutics ranks better than 90.23% on this metric.
Mineralys Therapeutics's quarterly market cap
declined
from Sep. 2025 ($2,994.50 Mil) to Dec. 2025 ($2,958.98 Mil) and
declined
from Dec. 2025 ($2,958.98 Mil) to Mar. 2026 ($2,233.71 Mil).
Mineralys Therapeutics's annual market cap
increased
from Dec. 2023 ($353.75 Mil) to Dec. 2024 ($613.31 Mil) and
increased
from Dec. 2024 ($613.31 Mil) to Dec. 2025 ($2,958.98 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mineralys Therapeutics's Enterprise Value for Today is $1,662.81 Mil.
Mineralys Therapeutics (NAS:MLYS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mineralys Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mineralys Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics (MLYS) has a Market Cap of $2,308.87 Mil as of Jul. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #139 out of 1422 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Mineralys Therapeutics' Market Cap too high?
Mineralys Therapeutics' current Market Cap is $2,308.87 Mil. The Biotechnology industry median Market Cap is 110.32. Mineralys Therapeutics' value of $2,308.87 Mil is 1993% above this industry median. Based on the distribution chart, Mineralys Therapeutics ranks #139 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Market Cap compare to NKTR and PHVS?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #139 out of 1422 companies for Market Cap. This places Mineralys Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 110.32. Mineralys Therapeutics' value of $2,308.87 Mil is 1993% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.32, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mineralys Therapeutics's current Market Cap of $2,308.87 Mil is 1993% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mineralys Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 110.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mineralys Therapeutics's current Market Cap is $2,308.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Market Cap of $2,308.87 Mil. The current Market Cap is $2,308.87 Mil and 1993% above the Biotechnology industry median of 110.32. Mineralys Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Market Cap is $2,308.87 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score
Get the complete analysis for MLYS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLYS has been successfully added to your 
